OPEN ACCESS Freely available online

Journal of Nanomedicine & Biotherapeutic Discovery

Commentary

Nanoparticle Platforms for Monoclonal Antibody Delivery

Sophia Bennett*

Department of Drug Delivery and Nanomedicine, Greenfield University of Pharmaceutical Sciences, Edinburgh, United Kingdom

DESCRIPTION

Nanoparticle Platforms for monoclonal antibody delivery represents an important area of investigation because it addresses several limitations that can restrict the clinical performance of biological medicines. In conventional formulations, therapeutic molecules may undergo rapid degradation, limited tissue distribution, short systemic exposure, or inefficient access to intracellular targets. Nanomedicine provides a means of altering these limitations by placing a therapeutic payload within a defined physicochemical environment. The carrier can influence circulation, tissue interaction, cellular uptake, intracellular trafficking, and release. This is particularly relevant for biotherapeutics because proteins, peptides, antibodies, and nucleic acids are sensitive to enzymatic degradation and changes in their surrounding environment. A useful formulation must therefore be considered as an integrated therapeutic system rather than simply as a drug enclosed within a nanoscale material.

The principal formulation challenge is preserving antibody activity while modifying distribution, residence time, and access to difficult tissue compartments. After administration, a nanocarrier encounters proteins, immune cells, endothelial barriers, extracellular matrices, and cellular membranes before the payload reaches its intended site of action. Particle size, surface charge, morphology, composition, and colloidal stability can influence each of these stages. A formulation that performs well in a simplified laboratory medium may behave differently in blood or diseased tissue. Formulation development should combine physicochemical characterization with biological testing. Encapsulation efficiency, payload integrity, release kinetics, particle-size distribution, surface properties, and stability are useful measurements, but they become more informative when linked to cellular uptake, pharmacodynamic activity, and tissue distribution.

Targeting is another major consideration. Passive accumulation may occur in tissues with altered vascular permeability, but this effect is variable and should not be assumed to occur equally across diseases or patients. Active targeting can involve antibodies, peptides, carbohydrates, aptamers, receptor ligands, or cell-derived components that promote interaction with selected cells. However, attachment of a targeting ligand does not automatically produce selective therapeutic delivery. Receptor abundance, ligand accessibility, protein-corona formation, endocytosis, receptor recycling, and tissue penetration can all modify performance. For many biotherapeutics, intracellular localization is as important as tissue localization. Demonstrating productive delivery therefore requires evidence that the payload reaches the biological compartment where it can exert its intended effect.

Safety and pharmacokinetics are central to translation. Nanocarriers can change the distribution and elimination of their associated payloads and may consequently alter both efficacy and toxicity. Interaction with complement proteins, macrophages, endothelial cells, and other immune components can influence circulation and organ accumulation. Repeated administration introduces additional considerations because immune recognition, clearance, or tissue retention may change over time. Safety assessment should therefore extend beyond simple cell viability assays and include appropriate evaluation of inflammatory responses, complement activation, hemocompatibility, organ distribution, degradation products, and dose-related effects. The relationship between carrier exposure and therapeutic activity should also be examined because a formulation that increases tissue concentration is not necessarily beneficial if the increase is accompanied by unacceptable toxicity.

Clinical translation presents a separate set of challenges. Laboratory formulations can be difficult to reproduce at manufacturing scale, and apparently minor changes in mixing, purification, raw materials, storage, or sterilization may influence particle characteristics. Biological payloads add another layer of complexity because their structural integrity and activity must be maintained throughout processing. Critical quality attributes should therefore be defined early, with analytical methods capable of detecting meaningful changes in the final product. Translational studies are strongest when formulation characteristics, exposure measurements, pharmacodynamic markers, and clinically relevant outcomes are evaluated together.

Correspondence to: Sophia Bennett, Department of Drug Delivery and Nanomedicine, Greenfield University of Pharmaceutical Sciences, Edinburgh, United Kingdom, E-mail: sophia.bennett@gmail.com

Received: 01-May-2025, Manuscript No. JNBD-25-44291; **Editor assigned:** 03-May-2025, PreQC No. JNBD-25-44291 (PQ); **Reviewed:** 16-May-2025, QC No. JNBD-25-44291; **Revised:** 23-May-2025, Manuscript No. JNBD-25-44291 (R); **Published:** 30-May-2025, DOI: 10.35248/2155-983X-25.15.316.

Citation: Bennett S (2025). Nanoparticle Platforms for Monoclonal Antibody Delivery. J Nanomedicine Biotherapeutic Discov. 15:316.

Copyright: © 2025 Bennett S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

The development in nanoparticle platforms for monoclonal antibody delivery is likely to depend on closer integration of nanomaterial engineering with molecular pharmacology, bioanalytics, toxicology, and clinically relevant disease models. Greater emphasis on quantitative biodistribution and intracellular delivery should help distinguish simple tissue accumulation from therapeutically productive delivery. Manufacturing and regulatory strategies must advance alongside discovery so that formulations can be produced reproducibly and evaluated against clearly defined quality criteria. Patient heterogeneity is also important because receptor expression, immune status, disease stage, tissue barriers, and prior treatment can influence nanomedicine performance. The most useful advances will therefore be those that connect formulation design with measurable biological mechanisms and clinically meaningful endpoints. Such an approach can strengthen the evidence required to move biotherapeutic nanomedicines from experimental platforms toward dependable therapeutic applications.